SCHEDULE 13G/A: Perceptive Advisors Discloses 5.3% Passive Stake in Arcellx, Inc.
Beneficial Ownership Disclosure
Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has disclosed a passive beneficial ownership of 5.3% in Arcellx, Inc.'s common stock.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G.
- The filing indicates beneficial ownership of 2,926,478 shares of Arcellx, Inc. Common Stock.
- This stake represents 5.3% of Arcellx, Inc.'s outstanding Common Stock.
- The ownership percentage is based on 55,072,693 shares of Common Stock outstanding as of April 4, 2025, as reported in Arcellx's Definitive Proxy Statement on Schedule 14A filed on April 17, 2025.
- Perceptive Life Sciences Master Fund, Ltd. directly holds the shares, with Perceptive Advisors LLC serving as its investment manager and Joseph Edelman as the managing member of Perceptive Advisors LLC.
- The Reporting Persons share both voting and dispositive power over the 2,926,478 shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the sentiment, maintaining a neutral stance.
Positives
- The disclosure of a significant 5.3% stake by an institutional investor like Perceptive Advisors indicates continued institutional interest and confidence in Arcellx, Inc.
Industry Context
This filing is a standard disclosure of a passive investment stake by an institutional investor in a publicly traded company, common in the biotechnology sector where specialized funds often take significant positions.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can be viewed positively as a vote of confidence from a major investor.
Key Dates
| Date | Description |
|---|---|
| 2025-03-31 | Date of event which requires filing of this statement. |
| 2025-04-04 | Date as of which 55,072,693 shares of Common Stock were reported outstanding, used as the basis for ownership percentage. |
| 2025-04-17 | Date Arcellx, Inc. filed its Definitive Proxy Statement on Schedule 14A, reporting shares outstanding. |
| 2025-05-15 | Date of filing of this Schedule 13G Amendment No. 3. |
Keywords
Arcellx Inc., Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund Ltd., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.